## BAX: Baxter International Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.1% below STRENGTH zone (3.0-6.0%); PEG 33.66 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($17.84)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Your Guide to the Baxter International, Inc. Lawsuit - A SueWallSt Podcast From Levi & Korsinsky**
- Source: KLAS 8 News Now | 20251201T075300 | Neutral | Relevance: 99%
- Levi & Korsinsky, LLP has released a podcast discussing a class action securities lawsuit filed against Baxter International, Inc. The lawsuit alleges that Baxter made false statements and/or concealed systemic defects in their Novum LVP product, leading to malfunctions, patient risks, and inadequate remedial actions. The firm is seeking investors who lost money due to alleged securities fraud between February 23, 2022, and July 30, 2025.

**2. Deadline Alert: Baxter International, Inc. (BAX)**
- Source: GlobeNewswire | 20251201T120000 | Neutral | Relevance: 99%
- Glancy Prongay & Murray LLP is reminding investors of Baxter International, Inc. (BAX) about an upcoming December 15, 2025 deadline to file a lead plaintiff motion in a class action lawsuit. The lawsuit alleges securities fraud, claiming Baxter made misleading statements and failed to disclose critical information regarding defects in its Novum IQ Large Volume Pump, which led to patient injuries and deaths. The firm is urging shareholders who suffered losses during the Class Period (February 23, 2022, to July 30, 2025) to contact them for potential claims.

**3. Investors SueWallSt Over Baxter International, Inc. Stock Drop - Contact Levi & Korsinsky to Join**
- Source: ABC4 Utah | 20251201T181500 | Neutral | Relevance: 99%
- A class action lawsuit has been filed against Baxter International, Inc. on behalf of investors who incurred losses due to alleged securities fraud between February 23, 2022, and July 30, 2025. Investors are encouraged to contact Levi & Korsinsky to join the lawsuit and seek recovery for their losses. Levi & Korsinsky, a firm specializing in complex securities litigation, has a track record of securing significant settlements for aggrieved shareholders.

**4. Your Guide to the Baxter International, Inc. Lawsuit - A SueWallSt Podcast From Levi & Korsinsky**
- Source: www.nbc4i.com | 20251201T075300 | Neutral | Relevance: 99%
- Levi & Korsinsky, LLP has released a podcast discussing a class action securities lawsuit filed against Baxter International, Inc. The lawsuit alleges that Baxter made false statements and/or concealed systemic defects in its Novum LVP product, leading to widespread malfunctions, patient injuries, and deaths. Investors who suffered losses due to alleged securities fraud between February 23, 2022, and July 30, 2025, are encouraged to contact Levi & Korsinsky.

**5. Deadline Alert: Baxter International, Inc. (BAX)**
- Source: GlobeNewswire | 20251201T120000 | Neutral | Relevance: 99%
- Glancy Prongay & Murray LLP reminds investors of Baxter International, Inc. (BAX) to file a lead plaintiff motion by December 15, 2025, in a class action lawsuit. The lawsuit alleges that Baxter made misleading statements and failed to disclose severe defects in its Novum IQ Large Volume Pump, which led to serious injuries and patient deaths. Baxter's stock price fell significantly after pausing shipments of the problematic device, injuring investors who purchased shares between February 23, 2022, and July 30, 2025.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $15 | $19 | -21% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.16M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 65.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 15.1% (+14.9%)
- Vanguard Group Inc: 12.2% (+0.5%)
- Dodge & Cox Inc.: 11.2% (+10.1%)
- Pzena Investment Man: 11.2% (+45.9%)
- State Street Corpora: 4.3% (+0.3%)

### Key Risks

1. Valuation stretched: PEG 33.7x requires aggressive growth execution.
2. Elevated short interest (9.7%): bears positioning against stock.
3. Long-term trend broken: trading 29.9% below SMA200.

### Catalysts

- Momentum building: MRS_10 improving +2.5% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 33.66 signals overvaluation risk, limited margin of safety. Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.4B |
| Beta | 0.61 |
| 52W Range | $17.40 - $37.74 |
| Short Interest | 9.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 33.66 |
| Forward P/E | 8.3 |
| Current P/E | 8.1 |
| YoY Growth | -2.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -0.4% to 2.1% (+2.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.9pp (needs >3.0% for momentum thesis). MRS_5 at 1.4% confirms short-term momentum alignment. Below SMA200 (0.70x), long-term trend not supportive. RSI neutral at 48.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.12% (CS: 83) | Neutral |
| RSI_14 | 48.1 | Neutral |
| MACD Histogram | 0.28 | Bullish |
| vs SMA20 | 1.046x | Above |
| vs SMA50 | 0.917x | Below |
| vs SMA200 | 0.701x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $19.08
- **Stop Loss:** $17.84 (6.5% risk)
- **Target:** $20.32 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 604
- **Position Value:** $11,524.32
- **Portfolio %:** 11.52%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-19 (Est: $0.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.60 | $0.69 | +15.4% |
| 2025Q2 | $0.61 | $0.54 | -11.5% |
| 2025Q1 | $0.48 | $0.55 | +13.8% |
| 2024Q4 | $0.53 | $0.58 | +9.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*